Troglitazone represents a new molecular entity class of insulin-sensitizing drugs, the thiazolidinediones, and is approved for the treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic drugs.1 Thiazolidinediones, including troglitazone, have recently been shown to have antiproliferative2 and anti-inflammatory3 effects in human cells. Because psoriasis is a proliferative, inflammatory disease of the skin, we hypothesized that in diabetic patients with poor glycemic control with coexisting psoriasis, oral administration of troglitazone would not only improve their glycemic control, but also produce significant resolution of their psoriasis.
Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of Psoriasis With Troglitazone Therapy. Arch Dermatol. 1998;134(10):1304–1305. doi:https://doi.org/
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: